Drugs / ANB-010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06185335 | Jul 2023 → Dec 2025 overdue | hemophilia A | Biocad | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ANB-010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06185335 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.” NCT06185335 ↗ |
| Route | Intravenous | “single inravenous infusion” NCT06185335 ↗ |
| Target | F8 | “Adeno-associated viral vector carrying the FVIII gene single infusion at dose 1.” NCT06185335 ↗ |